Meggle Introduces New High-Functionality Excipient
CombiLac is a lactose-based, co-processed excipient, designed to ease oral solid dosage form development and manufacture in direct compression.
Excipient supplier, Meggle has launched a new high-functionality excipient, CombiLac, which consists of the spray-dried, ternary admixture of alpha-lactose monohydrate, microcrystalline cellulose, and starch, all conforming with Ph. Eur., USP-NF, and JP compendial requirements.
The excipient is designed for direct compression applications but can also be used in other formulation development approaches, such as dry granulation. The good powder flow characteristics enhance solid dosage form weight uniformity and throughput in tablet production.
CombiLac compliments the differentiated functionality of Meggle’s co-processed excipients portfolio. According to the company, a well-defined manufacturing process is used to create these porous, spherical particles with a highly integrated structure that is inseparable by physical means.
Because of the improved compaction properties compared with an equivalent blend of the individual ingredients, CombiLac enables the production of robust tablets with minimal friability. Rapid, hardness-independent tablet disintegration offering effective API release can be achieved. In production, release testing is reduced due to its ternary composition.
Source: Meggle
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
